使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to the first quarter 2026 financial results conference call and webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
歡迎收聽 Zoetis 2026 年第一季財務業績電話會議與網路直播。今日會議由 Zoetis 投資人關係副總裁 Steve Frank 主持。
The presentation materials and additional financial tables are currently posted on the Investor Relations section of Zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of Zoetis.com.
簡報資料與其他財務表格目前已張貼於 Zoetis.com 的投資人關係專區。簡報投影片可由您(觀眾)自行控制,且不會自動往前播放。此外,本次電話會議結束約兩小時後,可透過撥入方式或於 Zoetis.com 投資人關係專區收聽重播。
(Operator Instructions)
(接線員指示)
Your line will be muted when you complete your question. When posing your question, please pick up the handset to allow optimal sound quality.
您提問結束後,您的線路將會被靜音。提問時,請拿起聽筒以確保最佳音質。
It is now my pleasure to turn the call over to Steve Frank.
現在我很榮幸將電話會議交給 Steve Frank。
Steve, you may begin.
Steve,您可以開始。
Steve Frank - VP:Investor Relations
Steve Frank - VP:Investor Relations
Thank you, operator. Good morning, everyone, and welcome to the Zoetis first-quarter 2026 earnings call. I am joined today by Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Chief Financial Officer. This morning, we issued a press release announcing our first-quarter 2026 financial results.
謝謝,接線員。各位早安,歡迎參加 Zoetis 2026 年第一季財報電話會議。今天與我一同出席的有執行長 Kristin Peck,以及財務長 Wetteny Joseph。今天早上,我們已發布新聞稿,公布 2026 年第一季財務結果。
Before we begin, I would like to remind you that the release and corresponding earnings presentation, which we will reference during this call, are available on the Investor Relations section of our website and that many of our statements today may be considered forward-looking statements and that actual results could differ materially from those projections.
在開始之前,我想提醒各位:我們將在本次會議中引用的新聞稿與相對應的財報簡報,已可於本公司網站的投資人關係專區取得;此外,我們今天的許多陳述可能構成前瞻性陳述,實際結果可能與這些預測有重大差異。
For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release and in our company's reports filed with the SEC. Additionally, today's remarks will include certain non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable US GAAP measures can be found in our earnings press release and our company's 8-K filing dated today, May 7, 2026.
關於可能導致結果出現差異的若干因素之清單與說明,請參閱今日新聞稿以及本公司向美國證券交易委員會(SEC)提交之報告中的前瞻性陳述。此外,今天的發言將包含若干非 GAAP 財務衡量指標。這些非 GAAP 財務衡量指標與最直接可比的美國 GAAP 指標之調節表,可見於我們的財報新聞稿,以及本公司今日(2026 年 5 月 7 日)提交的 8-K 文件。
We also reference reported and organic operational growth. Organic operational growth excludes the effect of foreign currency, as well as acquisitions and divestitures, which individually impacts Zoetis growth by 1% or more. Unless otherwise stated, all revenue growth performance metrics will be based on organic operational performance.
我們也會提及報告基礎與有機營運成長。有機營運成長排除外幣影響,以及併購與處分的影響(上述因素若單獨對 Zoetis 成長造成 1% 或以上的影響)。除非另有說明,所有營收成長表現指標皆以有機營運表現為基礎。
And with that, I turn the call over to Kristin.
接下來,我把電話會議交給 Kristin。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Thank you, Steve. Good morning, everyone, and welcome to our fourth-quarter 2026 earnings call. I'll start with the headline numbers we recorded today. On an organic operational basis, revenue was flat, and adjusted net income grew 1%. Our international segment delivered 10% organic operational revenue growth, while the US Declined 8%.
謝謝你,Steve。各位早安,歡迎參加我們 2026 年第四季財報電話會議。我先從今天的重點數字開始。以有機營運基礎計算,營收持平,調整後淨利成長 1%。國際事業部有機營運營收成長 10%,而美國則下滑 8%。
By species, Livestock delivered 12% organic operational revenue growth, while companion animals declined 4% operationally. To level set, the quarter unfolded differently than expected, particularly in companion animals. We saw a convergence of interconnected dynamics shaping decisions at the point of care. I'll outline each, along with their impact, and what we're doing about it. First, pricing in veterinary clinics continues to rise. Though at a slower pace, adding to multi-year increases and lower clinic traffic.
以物種別來看,經濟動物(Livestock)有機營運營收成長 12%,而伴侶動物在營運基礎上下降 4%。為了先建立共同基準,本季的發展與我們原先預期不同,尤其是在伴侶動物方面。我們看到多項相互關聯的動態在照護現場(point of care)共同影響決策。我將逐一說明各項因素、其影響,以及我們正在採取的因應作為。第一,獸醫診所的定價仍在上升。雖然增速放緩,但仍疊加在多年來的漲幅之上,且診所來客量較低。
Second, pet owners demonstrated increased price sensitivity, with softer demand for premium products in preventative and chronic care where Zoetis leads, amid a more cautious spending environment.
第二,飼主展現出更高的價格敏感度;在較為謹慎的支出環境下,對於預防與慢性照護中 Zoetis 領先的高端產品,需求轉弱。
Third, competition intensified across key pet care categories, including dermatology and parasiticides, with additional pressure in vaccines from certain generics. While competition is not new to us, what was different in Q1 was the pace and level of activity. More entrants across more markets, with competitors leaning more heavily in aggressive pricing and incentives for extended periods of time to drive share, particularly in a softer end market.
第三,關鍵寵物照護品類的競爭加劇,包括皮膚科與驅寄生蟲產品;疫苗方面亦受到部分學名藥的額外壓力。競爭對我們而言並不陌生,但第一季不同之處在於活動的速度與強度。更多競爭者進入更多市場,且競品更大幅度地採取激進定價與獎勵措施,並在更長期間內推動市占,尤其是在終端市場較疲弱的情況下。
And fourth, in contrast to what we've seen historically, these new entrants have not yet translated into overall market expansion. Taken together, the result is a more price-sensitive and competitive environment. Pet owners delayed routine visits, extended dosing, and had new lower-cost options, compounded by winter storms that further reduced clinic visits, all without the benefit of underlying market growth.
第四,與我們過往所見不同的是,這些新進者尚未帶動整體市場擴張。綜合而言,結果是一個更具價格敏感度且競爭更激烈的環境。飼主延後例行就診、拉長給藥間隔,且有新的低成本選擇;再加上冬季風暴進一步降低診所就診量,而同時缺乏底層市場成長的支撐。
As a market leader with significant share in premium products, we are at a point where our growth is less driven by new product cycles as we progress our blockbuster pipeline, which we expect to begin delivering significant value for the end of '27 and into '28. These dynamics increased our exposure, particularly compared to new entrants just launching into these categories and competing primarily on price. You see these dynamics most clearly in our Key Dermatology and Simparica franchises, where we saw declines in the quarter.
作為在高端產品擁有顯著市占的市場領導者,隨著我們推進重磅產品(blockbuster)研發管線(我們預期將於 2027 年底至 2028 年開始帶來顯著價值),我們的成長在此階段較不由新產品週期所驅動。這些動態提高了我們的曝險程度,特別是相較於剛進入這些品類、主要以價格競爭的新進者。在我們的 Key Dermatology 與 Simparica 產品線中,這些動態最為明顯,本季我們看到下滑。
In Key Dermatology, even with the industry's broadest and most differentiated portfolio, we were not able to fully offset the combined impact of increased owner price sensitivity and the lack of market expansion, which drove share pressure. That said, we do see a path for the market to return to growth over time, and we continue to invest in long-term growth while taking decisive near-term actions to compete more effectively.
在 Key Dermatology 方面,即使我們擁有業界最廣且差異化最高的產品組合,仍無法完全抵銷飼主價格敏感度上升與市場未擴張的綜合影響,因而造成市占壓力。儘管如此,我們確實看到市場隨時間回到成長的路徑;同時,我們在持續投資長期成長的同時,也採取果斷的短期行動,以更有效地競爭。
We also remain on track advancing Cytopoint Plus, which we expect will further strengthen our dermatology leadership. In parasiticides, this imperative franchise saw simpler dynamics, but more pronounced in the US. Fewer patient visits drove lower prescription volumes and impacted new patient starts and compliance, with retail growth also moderating.
我們也持續按計畫推進 Cytopoint Plus,我們預期這將進一步強化我們在皮膚科的領導地位。在驅寄生蟲產品方面,這個關鍵產品線的動態較為單純,但在美國更為明顯。就診人次減少導致處方量下降,並影響新病患起始用藥與用藥依從性(compliance),同時零售端成長也趨於放緩。
Importantly, in the US, while competitive launches earlier in 2025 put pressure on share, largely through aggressive promotion, we saw that stabilizing, with share levels nearing prior year by quarter end, and puppy share still well above our overall patient share.
重要的是,在美國,雖然 2025 年初的競品上市主要透過激進促銷對市占造成壓力,但我們看到情勢正在穩定;至本季末,市占水準已接近前一年同期,而幼犬市占仍明顯高於我們整體病患市占。
International markets continue to deliver strong growth in the corner, supported by the ongoing geographic expansion of our portfolio, partially offsetting the US despite pressure on revenue, we are pleased with the improving US Share trends and our ability to maintain a leadership position in a more constrained market.
國際市場持續在本季繳出強勁成長,受惠於我們產品組合持續進行的地域擴張,儘管營收承壓,仍部分抵銷了美國的影響;我們對美國市占趨勢的改善,以及在更受限的市場中維持領導地位的能力感到滿意。
And across both franchises, while you can see these impacts geographically in today's results. This is more fundamentally about portfolio mix against the backdrop of the shifting demand trends I mentioned. Demand softness across key developed pet care markets underscores that this is not isolated, while emerging markets continue to provide runway for expansion.
而在這兩個產品線中,雖然您可在今日結果中看到這些影響在地理區域上的呈現。但更根本的是,在我所提到的需求趨勢轉變背景下,產品組合結構(portfolio mix)所帶來的影響。關鍵已開發寵物照護市場的需求疲弱,凸顯這並非單一地區的現象;同時,新興市場仍持續提供擴張空間。
Now, turning to OA Pain. While the broader trends for this category are consistent with what we saw in [Durham and Paris], competitive dynamics are less of a factor here.
接著談 OA 疼痛(骨關節炎疼痛)。雖然此品類的整體趨勢與我們在 [Durham and Paris] 所看到的情況一致,但此處的競爭動態影響相對較小。
In the quarter, Solensia continued to perform well, while Librela drove the year-over-year OA decline. That said, sequentially, Librela has stabilized in the US. With roughly flat growth. This US Stabilization reflects the continued execution across our multi-pronged strategy, with a strong emphasis on medical education and specialist engagement, which is helping build veterinary prescribing confidence.
本季 Solensia 持續表現良好,而 Librela 則導致 OA 業務年對年下滑。不過,從季對季來看,Librela 在美國已趨於穩定。成長大致持平。這項美國的穩定表現,反映我們多管齊下策略的持續落實,並特別著重醫學教育與專科醫師互動,正協助建立獸醫開立處方的信心。
Findings, like those published by the Veterinary Medicines Directorate in the UK, confirming Librela's positive benefit-risk profile are important inputs into the education effort, and we saw an improvement in our conversations with vets in that market following the report. And as mentioned on previous calls, we expect additional label updates. These are a normal part of the ongoing regulatory review and provide more information to support appropriate use.
研究結果(例如英國獸醫藥品管理局(Veterinary Medicines Directorate)所發布、確認 Librela 具備正向的效益—風險概況)是教育推廣工作的重要投入;在該報告發布後,我們看到在該市場與獸醫的對話有所改善。此外,如同先前電話會議中提到的,我們預期還會有額外的標籤更新。這些是持續性法規審查的正常一環,並提供更多資訊以支持適當使用。
We are also in the early phases of our Lenivia and Portela launches in certain European markets and Canada, which will expand the OAP franchise and support the long-term growth trajectory, and early feedback continues to be encouraging. Looking more broadly across companion animals, diagnostics continues to be a source of strength.
我們也正處於 Lenivia 與 Portela 在部分歐洲市場及加拿大上市初期階段,這將擴大 OAP 產品系列並支持長期成長軌跡,而早期回饋仍然令人鼓舞。更廣泛來看,在伴侶動物領域,診斷業務仍持續是我們的強項來源。
Performance in the quarter was driven by strong international momentum, with modest UF growth against a strong comparison period and slower placement activity. Expansion in reference labs drove performance alongside strength in chemistry and hematology, with continued progress in images. This is consistent with the broader shift we see across pet care, where spending remains resilient in areas tied to urgent and diagnostic care.
本季表現主要由強勁的國際動能所帶動;在強勁的比較基期以及設備裝機活動較慢的情況下,UF 成長溫和。參考實驗室的擴張帶動表現,同時化學與血液學維持強勢,影像業務亦持續取得進展。這與我們在整體寵物照護中觀察到的更廣泛轉變一致:與急迫性醫療與診斷照護相關的支出仍具韌性。
Turning to livestock, we again delivered broad-based performance. Underlying market conditions remained favorable with sustained protein demand, driving stronger producer profitability and enabling continued investment in herd health and productivity.
轉向經濟動物方面,我們再次交出全面性的表現。在蛋白質需求持續的帶動下,基礎市場環境仍然有利,推升生產者獲利能力,並使其得以持續投資於畜群健康與生產力。
Performance was supported by our BIOS portfolio, particularly in cattle and poultry, where disease outbreaks and increased adoption reinforced the importance of prevention, alongside strong performance in fish, benefiting from favorable vaccination timing and in swine. As a result, livestock remains a strong source of growth, with solid end-market demand and a more focused portfolio following the MFA divestiture.
本季表現受到我們 BIOS 產品組合的支持,特別是在牛與家禽領域;疾病爆發與採用率提升強化了預防的重要性;同時魚類業務受惠於有利的疫苗接種時點,豬隻業務亦表現強勁。因此,經濟動物仍是強勁的成長來源,終端市場需求穩健,且在 MFA 出售後,產品組合更為聚焦。
Our performance this quarter underscores the value of our diversified portfolio, while also highlighting where we need to take action to maintain our leadership and regain momentum in pet care markets, where the consumer is under pressure and the competition is increasing.
本季表現凸顯我們多元化產品組合的價值,同時也指出我們需要採取行動之處,以維持領導地位並在寵物照護市場重拾動能;在該市場中,消費者承受壓力且競爭加劇。
We are doing this on multiple fronts. First, we are sharpening execution across our core commercial levers with a clear focus on capturing demand more effectively. That starts with how we engage veterinarians, where we are focusing on integrated solutions that make better use of our broad portfolio and help strengthen clinic economics.
我們正從多個面向推進。首先,我們正強化核心商業槓桿的執行力,明確聚焦於更有效地掌握需求。這從我們與獸醫的互動方式開始:我們聚焦於整合式解決方案,更好地運用我們廣泛的產品組合,並協助強化診所經濟效益。
We're also focused on improving execution in priority markets through localized action plans to more consistently convert demand into prescriptions. For pet owners, we're investing in targeted DTC activity, simplifying point-of-sale choices with clear loyalty and affordability options, and ensuring convenient, authorized access across clinics, retail, and home delivery. And in livestock, we're reinforcing continuity of supply. And responsiveness in key products and markets, ensuring demand is not constrained by availability.
我們也聚焦於透過在重點市場的在地化行動計畫改善執行,以更一致地將需求轉化為處方。對於寵物飼主,我們投資於精準的 DTC(直接面向消費者)活動,透過清楚的忠誠方案與可負擔選項簡化銷售點選擇,並確保在診所、零售與到府配送之間提供便利且授權的取得管道。在經濟動物方面,我們正強化供應的連續性。並提升在關鍵產品與市場的回應速度,確保需求不會因供應可得性而受限。
Second, we're accelerating our science-to-scale model, shortening time from approval to launch and translating that into growth. That includes prioritizing near-term launches and advancing convenience-led lifecycle innovation with our portfolio to create new ways to compete, including long-acting MAVs, Procerta, and the recent Canadian approval of Convenia RTU, which expands access through a ready-to-use, cost-effective formulation.
第二,我們正加速「從科學到規模化」的模式,縮短從核准到上市的時間,並將其轉化為成長。這包括優先推動近期上市項目,並以便利性導向的產品生命週期創新推進我們的產品組合,創造新的競爭方式,包括長效型 MAVs、Procerta,以及近期在加拿大核准的 Convenia RTU;後者透過即用型、具成本效益的配方擴大可近性。
Third, we announced an agreement to acquire Neogen's Animal Genomics Business, expanding our capabilities in livestock genetics. This reflects our broader approach to targeted business development, where we continue to be strategic in pursuing opportunities to unlock new sources of growth over time.
第三,我們宣布已達成協議,將收購 Neogen 的動物基因體業務,以擴大我們在經濟動物遺傳學方面的能力。這反映我們更廣泛的精準業務發展策略:我們持續以策略性方式追求機會,隨時間推進解鎖新的成長來源。
Finally, we are sharpening our approach to capital allocation, while continuing to invest in our key growth priorities. As reflected in our adjusted net income, we acted decisively as growth softened in the quarter and launched a comprehensive cost and productivity program, further tightening discretionary spending, driving procurement and operating efficiencies, and assessing organizational levers to deliver a leveraged P&L in 2026 and beyond.
最後,在持續投資於關鍵成長優先事項的同時,我們正強化資本配置的方法。如我們的調整後淨利所反映,隨著本季成長趨緩,我們果斷採取行動並啟動全面性的成本與生產力計畫,進一步收緊非必要支出,推動採購與營運效率,並評估組織槓桿,以在 2026 年及之後實現具槓桿效應的損益表(P&L)。
We have clear priorities and a proven track record of execution, and we are confident these actions will position us to better navigate the current environment and improve performance over time.
我們有明確的優先事項與經驗證的執行紀錄,並有信心這些行動將使我們更能因應當前環境,並隨時間改善表現。
Looking ahead, our focus is on improving our trajectory over the balance of the year. Zoetis is providing updated guidance based on the current operating environment and the presentation of its financials for fiscal year alignment.
展望未來,我們的重點是在今年剩餘期間改善成長軌跡。Zoetis 將基於目前的營運環境以及其財務報表為配合會計年度一致性之呈列方式,提供更新後的指引。
For the full year, on an organic operational basis, we expect revenue growth of 2% to 5% and adjusted net income growth of 2% to 6%. This quarter reflects pressure in parts of our companion animal portfolio, where market growth has slowed and competition has intensified. As we bridge to Glenus's next wave of innovation-driven growth.
就全年而言,以有機營運基礎計算,我們預期營收成長 2% 至 5%,調整後淨利成長 2% 至 6%。本季反映我們部分伴侶動物產品組合面臨壓力,市場成長放緩且競爭加劇。在我們銜接至 Glenus 下一波由創新驅動的成長之際。
Execution, commercial effectiveness, portfolio optimization, and enhanced GOP discipline will play a greater role in driving performance, especially in this environment. We are actively managing through this period, and our conviction in the underlying strength of our business and what enables the lattice to win has not changed. Animal health remains a durable and essential industry. Underpinned by the strength of the human-animal bond and sustained global demand for protein.
在此環境下,執行力、商業效能、產品組合最佳化,以及更強的 GOP 紀律,將在推動表現方面扮演更重要的角色。我們正積極管理並度過這段期間,而我們對業務基本面實力的信念,以及使 Zoetis 取勝的關鍵要素,並未改變。動物保健仍是具韌性且不可或缺的產業。其基礎來自人與動物之間連結的力量,以及全球對蛋白質的持續需求。
We operate from a position of strength. With leadership in the category, we've helped build a diversified portfolio across species, geographies, and channels, and the colleagues and capabilities to compete effectively in a dynamic environment.
我們以強勢地位營運。憑藉類別領導地位,我們協助建立了跨物種、地理區域與通路的多元化產品組合,以及能在動態環境中有效競爭的同仁與能力。
Our near-term focus is clear. Sharpen commercial execution, and compete with precision while positioning the business to deliver the next wave of innovation. We are doing this with a pipeline that includes 12 potential blockbusters and more than $7 billion in additional market opportunity as we extend our leadership into entirely new categories of care.
我們的短期重點很明確。強化商業執行,以精準方式競爭,同時讓業務具備交付下一波創新的定位。我們正透過研發管線來推進,其中包含 12 個潛在重磅產品(blockbusters),以及超過 70 億美元的新增市場機會,因為我們將領導地位延伸至全新的照護類別。
We have helped define the standards of care that exist today, and we expect to play a leading role in what comes next as we deliver our next wave of innovation. We've demonstrated our ability to perform in different environments, and we will do so again.
我們曾協助定義今日存在的照護標準,並預期在交付下一波創新時,將在未來發展中扮演領導角色。我們已證明能在不同環境中表現出色,而我們也將再次做到。
And we remain committed to delivering long-term value for our shareholders to executing with discipline today while continuing to invest in the innovation that will drive tomorrow's growth. With that, I will hand it over to Wetteny.
我們仍致力於為股東創造長期價值:在今日以紀律執行,同時持續投資於將驅動明日成長的創新。接下來,我將交給 Wetteny。
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Thank you, Kristin, and good morning, everyone. As Kristin highlighted, our quality performance reflects multiple conversion dynamics. Macro-driven price sensitivity weighing on certain aspects of pet owner spending. Ongoing pressure on vet clinic visits and on increasing the competitive landscape in which price continues to be a key differentiator.
謝謝你,Kristin,各位早安。如 Kristin 所強調,我們的整體表現反映了多重轉換動態。由總體環境驅動的價格敏感度,正在影響寵物飼主支出的某些面向。獸醫診所就診次數持續承壓,以及競爭版圖擴大,在其中價格仍是關鍵差異化因素。
These dynamics have led to performance that is below our expectations this quarter, but we are confident in our near-term efforts to drive demand and cost discipline, as well as our industry-leading portfolio and pipeline, which we believe will continue to drive growth in the longer-term.
這些動態使本季表現低於我們的預期,但我們對短期內推動需求與成本紀律的努力,以及我們業界領先的產品組合與研發管線充滿信心;我們相信這些將在較長期持續帶動成長。
Now I'll walk you through our financial results for the first quarter, which, as a reminder, are reflective of an aligned calendar year. For the first quarter, we reported global revenue of $2.3 billion, going 3% on a reported basis and flat on an organic operational basis, with 2% growth coming from price, offset by 2% decline in volume.
接下來我將帶各位回顧第一季的財務結果;提醒一下,這些結果反映的是已對齊的曆年基礎。第一季我們公布全球營收為 23 億美元,以報告基礎計成長 3%,以有機營運基礎計則持平;其中價格帶來 2% 成長,但被銷量下滑 2% 所抵銷。
As we previewed last quarter. Our Q1 2026 financial results were positively impacted by certain operational changes and in connection with our fiscal year alignment for subsidiaries outside of the United States. As referenced in our press release this morning and now posted under Supplemental Materials in the Quarterly Results section of our Investor Relations website, we have provided additional information in connection with our fiscal year alignment, including recapped financial information on a quarterly basis for 2025 and annually for 2024 and 2025 to help with comparisons.
如同我們在上一季所預告的。我們 2026 會計年度第一季的財務結果,因若干營運變更以及與美國以外子公司會計年度對齊相關事項而受到正面影響。如同我們今早新聞稿所提及,且現已張貼於我們投資人關係網站「季度業績」區的「補充資料」之下,我們已就會計年度對齊提供額外資訊,包括按季度重述的 2025 年財務資訊,以及 2024 年與 2025 年的年度資訊彙整,以利比較。
You will note that for most quarters, the overall differences are relatively immaterial. However, I draw your attention to the $128 million revenue decrease on a recast basis from our previously reported Q4 2025 revenue. See the recast information on page 3 of the supplemental material.
您會注意到,多數季度的整體差異相對不具重大性。然而,我要特別提醒各位注意:在重述基礎下,相較於我們先前報告的 2025 年第四季營收,營收減少了 1.28 億美元。請參閱補充資料第 3 頁的重述資訊。
As we described last quarter, certain operational changes made in connection with our fiscal year alignment resulted in the acceleration of the timing of sales, which led to an approximate $30 million increase in the sales that we reported for our international segment for Q4 2025. The balance of the $128 million decrease in recast Q4 2025 revenue, or approximately $100 million, resulted in a corresponding increase in Q1 2026 sales in our international segment.
如同我們上一季所說明,為配合會計年度對齊而進行的若干營運變更,導致銷售時點提前,使我們在 2025 年第四季所報告的國際事業部銷售額約增加 3,000 萬美元。在重述後的 2025 年第四季營收減少 1.28 億美元中,其餘部分(約 1 億美元)則對應為 2026 年第一季國際事業部銷售額的增加。
This $100 million difference was driven by the change that we previously referenced in the timing of price increases in certain international markets and the delayed processing of customer orders that we referenced in our full-year 2025 results, as well as by differences in the performance of the business in comparing Q4 2025 to a stronger Q4 2024.
這 1 億美元的差異,主要來自我們先前提及的部分國際市場調價時點變更,以及我們在 2025 全年業績中提到的客戶訂單處理延遲;此外,亦受到比較 2025 年第四季與更強勁的 2024 年第四季時,業務表現差異的影響。
Excluding the approximately $100 million that shifted from Q4 2025 to early 2026 as a result of our fiscal year alignment, globally, we would have seen a 5% organic operational decline in the quarter. Adjusted net income of $646 million with 2% on a reported basis and 1% on an organic operational basis.
若排除因會計年度對齊而自 2025 年第四季移轉至 2026 年初的約 1 億美元,從全球角度看,本季有機營運將下滑 5%。調整後淨利為 6.46 億美元;以報告基礎計為成長 2%,以有機營運基礎計為成長 1%。
Turning to our franchises. Our global companion animal portfolio posted $1.5 billion in revenue, declining 4%. Key Dermatology recorded $347 million in revenue, down 11% versus the prior year.
接著談我們的產品事業群。我們的全球伴侶動物產品組合營收為 15 億美元,下滑 4%。皮膚科核心產品營收為 3.47 億美元,較去年同期下降 11%。
Consumer sentiment is pressuring aspects of pet owner spend in several key markets. We are facing increased competition globally for Apoquel, and despite our strong label, twice has played a larger role in the decision process.
消費者信心正在壓抑多個關鍵市場中飼主的部分支出。我們在全球面臨 Apoquel 的競爭加劇;儘管我們的標籤(適應症/核准內容)具優勢,但「價格」在決策過程中扮演了更大的角色。
While Cytopoint is also impacted by the VET claim dynamic, as a monoclonal antibody with a longer duration of treatment, Cytopoint switching to recent JAK-EYE competitors has been low.
雖然 Cytopoint 也受到獸醫端(VET)申索動態的影響,但作為一種治療持續時間較長的單株抗體,Cytopoint 轉換至近期 JAK-1 競品的情況一直偏低。
Our OA Pain meds, Librela and Valencia, posted a combined $140 million in revenue, declining 8%. Librela sales were $101 million, declining 13%. The bell trends have stabilized in the US, where we saw encouraging signs that our efforts are gaining traction.
我們的 OA 疼痛用藥 Librela 與 Valencia 合計營收 1.40 億美元,下滑 8%。Librela 銷售額為 1.01 億美元,下滑 13%。在美國,相關趨勢已趨於穩定,我們也看到令人鼓舞的跡象,顯示我們的努力正逐步奏效。
Valencia posted $39 million in revenue, growing 6%. Our Simparica franchise contributed $385 million globally, declining 1%. Simparica Trio declined 1% on sales of $297 million, while Simparica declined 3% on sales of $88 million.
Valencia 營收為 3,900 萬美元,成長 6%。我們的 Simparica 產品系列全球貢獻 3.85 億美元,下滑 1%。Simparica Trio 銷售額 2.97 億美元,下滑 1%;Simparica 銷售額 8,800 萬美元,下滑 3%。
Additionally, we have seen recent generic competition impacting two companion animal products: Convenia, an antibiotic treatment for bacterial skin infections, and Cerenia, the market-leading small animal and Thiomedic. While not considered part of our innovative core, these brands are both blockbusters and have lost meaningful share in the quarter due to price-driven generic competition.
此外,我們也看到近期學名藥競爭影響兩項伴侶動物產品:Convenia(用於細菌性皮膚感染的抗生素治療)以及 Cerenia(市場領先的小動物與 Thiomedic)。雖然不被視為我們創新核心的一部分,這兩個品牌皆為重磅產品,且因價格驅動的學名藥競爭,本季市占出現顯著流失。
Our global companion animal diagnostics business posted $113 million in revenue, growing 10%, driven by expansion of our reference lab business, as well as growth in chemistry and hematology, driven by our recently launched Vetscan OptiCell.
我們的全球伴侶動物診斷業務營收為 1.13 億美元,成長 10%,主要由參考實驗室業務擴張所帶動,並受惠於化學與血液學的成長;該成長由我們近期推出的 Vetscan OptiCell 所驅動。
Moving on to Livestock, which performed well in the quarter on $720 million in global revenue, growing 12%, with growth-based growth across geographies and species, as well as price and volume. Favorable producer economics drove higher demand, particularly in cattle. Combined with improved product supply and commercial wins, this provides a solid foundation for sustained livestock growth, further supported by the long-term secular tailwind of rising global protein consumption.
接著看畜牧業務,本季表現良好:全球營收 7.20 億美元,成長 12%;各地區與各物種均呈現成長,且同時受惠於價格與銷量。有利的生產者經濟狀況帶動需求提升,尤其是在牛隻方面。再加上產品供應改善與商業端的勝出,為畜牧業務的持續成長奠定穩固基礎;長期而言,全球蛋白質消費上升的結構性順風亦將進一步支撐。
While our performance is driven by the declines in our companion animal business in the US. And certain developed markets internationally, this quarter highlights the benefit that having a global cross-species portfolio can have in challenging market conditions.
雖然我們的整體表現受到美國伴侶動物業務下滑的影響,以及國際上部分已開發市場的影響,但本季凸顯了在艱困市場環境下,擁有跨物種的全球產品組合所能帶來的效益。
Now, let's move on to our second result for the quarter. US Revenue was $1.1 billion in the quarter, declining 8%. US Companion animal posted $865 million, declining 11%. Before going into our brand performance, I wanted to highlight some of the broader impacts we've seen across our US Japan animal business. The global trends we have mentioned around competition and consumer price sensitivity are very prevalent in the US Market.
現在,讓我們進入本季的第二項結果。本季美國營收為 11 億美元,下滑 8%。美國伴侶動物業務營收為 8.65 億美元,下滑 11%。在深入品牌表現之前,我想先強調我們在美國伴侶動物業務所觀察到的一些更廣泛影響。我們先前提到的競爭與消費者對價格敏感等全球趨勢,在美國市場尤為明顯。
Additionally, distributor and retail channel purchasing patterns were also a headwind this quarter, reflecting the lower end-market demand. Historically. Q1 distributor inventories start the quarter higher than they ended, as distributors typically buy ahead of price increases and promotions.
此外,經銷商與零售通路的採購模式本季也形成逆風,反映終端市場需求較弱。從歷史來看,第一季經銷商庫存通常在季初高於季末,因為經銷商往往會在漲價與促銷前提前進貨。
This quarter, our promotions underperformed expectations and end-market demand softened, so distributors and retail partners took longer to work through their opening inventories and engaged in less replenishment activity. As a result, our sales info distributors and retail partners lagged their sales out to customers compared with prior-year quarters. These overarching drivers have impacted much of our US Companion animal portfolio.
本季,我們的促銷表現不如預期且終端需求轉弱,因此經銷商與零售夥伴花了更長時間消化期初庫存,補貨活動也較少。因此,相較於去年同期季度,我們對經銷商與零售夥伴的銷售(sell-in)落後於他們對客戶的銷售(sell-out)。這些整體驅動因素影響了我們美國伴侶動物產品組合中的多數品項。
Our key dermatology products posted $215 million in revenue, declining 13% in the US. Apoquel has continued to face competitive headwinds, consistent with our expectations, with price remaining the primary differentiator, driving some shifts toward lower-cost alternatives.
我們的皮膚科核心產品在美國營收為 2.15 億美元,下滑 13%。Apoquel 持續面臨競爭逆風,符合我們的預期;價格仍是主要差異化因素,推動部分需求轉向較低成本的替代方案。
However, the impact has been more pronounced than we had expected. Share loss is being amplified by their market, with declining patient volume in the clinic. Unlike prior competitive cycles, we do not currently have the benefit of underlying market expansion to cushion the revenue effect of competitive share shifts, though we do see a path for the market to return to growth over time, with significant untreated and undertreated dogs in the space.
然而,影響程度比我們原先預期更為明顯。市占流失在市場層面被放大,因診所端的就診量正在下降。不同於以往的競爭循環,我們目前並未受惠於底層市場擴張來緩衝競爭市占變動對營收的影響;不過,鑑於該領域仍有大量未治療與治療不足的犬隻,我們確實看到市場隨時間回到成長的路徑。
Tidal point trends were consistent with the global picture, primarily impacted by the vet cleaning dynamics rather than jack-eye competition.
Cytopoint 的趨勢與全球情況一致,主要受到獸醫端申索動態的影響,而非 JAK-1 競爭。
The US Simparica franchise reported $238 million in revenue, declining 8% in the quarter. Simparica Trio posted $222 million in sales, declining 8%. Despite modest year-over-year declines due to additional entrance, our share has improved sequentially versus the second-half of last year when we saw the impact of competitive launch promotions which pressured our share, but also expanded the triple combination market.
美國 Simparica 產品系列本季營收為 2.38 億美元,下滑 8%。Simparica Trio 銷售額為 2.22 億美元,下滑 8%。儘管因新增進入者而出現溫和的年減,我們的市占較去年下半年呈現環比改善;當時我們受到競品上市促銷的影響而承壓,但也擴大了三合一組合市場。
A dynamic that is not providing the same market tailwind in the quarter. We continue to see market contraction, with softness in the clinic driven by lower flea ticket heartworm visits, as well as a slowing of alternative channel sales driven partly by script denials in retail. Our market-leading share in puppies remains stable.
但這種動態在本季並未帶來同樣的市場順風。我們持續看到市場收縮:診所端因跳蚤/蜱蟲與心絲蟲就診次數下降而走弱;替代通路銷售也放緩,部分原因是零售端處方遭拒。我們在幼犬市場的領先市占仍維持穩定。
In the US, our OA Pain mAbs posted $65 million, declining 15%. Zebrela contributed $37 million, declining 22%. US Librela revenue increased sequentially for the first time in six quarters, and vet and pet owner satisfaction ratings remained stable. Additionally, despite declines in the [canine] OA market, our patient share has remained stable since the second-half of 2025.
在美國,我們的OA疼痛mAbs營收為6,500萬美元,下滑15%。Zebrela貢獻3,700萬美元,下滑22%。美國Librela營收在連續六個季度後首次出現環比成長,且獸醫與寵物主人的滿意度評分維持穩定。此外,儘管[犬]OA市場下滑,我們的病患市占自2025年下半年以來仍保持穩定。
Looking ahead, the comparative periods become more favorable as the year progresses, and combined with the stabilization we are seeing, we believe the underlying foundation of the business continues to strengthen.
展望未來,隨著年度推進,對比基期將更為有利;再加上我們目前看到的趨於穩定,我們相信業務的基本面持續強化。
Valencia grew 2% in the quarter on $18 million in sales, with feline 4A visits holding relatively flat year-over-year.
Valencia本季在1,800萬美元銷售額的帶動下成長2%,貓科4A就診次數年對年大致持平。
Generic competition in Convenia and Cerenia also contributed to the US Companion animal decline. Our US Lifestyle business posted broad-based growth of 7% in the quarter, reporting $225 million in sales. We saw growth across all species, driven primarily by cattle, on improved supply of ceftiofur, as well as the impact of strong demand generated from our spring promotions.
Convenia與Cerenia的學名藥競爭也導致美國伴侶動物業務下滑。我們的美國Lifestyle業務本季呈現廣泛成長7%,銷售額達2.25億美元。我們在所有物種均見到成長,主要由牛隻帶動,受惠於頭孢噻呋(ceftiofur)供應改善,以及春季促銷帶來的強勁需求影響。
Poultry and swine also delivered meaningful contributions, with poultry growth driven by increased vaccine adoption and disease outbreaks, and swine benefiting from improved supply.
家禽與豬隻也做出顯著貢獻;家禽成長由疫苗採用率提升與疾病爆發所驅動,而豬隻則受惠於供應改善。
Moving on to our international segment for the quarter, revenue grew 17% on a reported basis and 10% on an organic operational basis, posting $1.1 billion in revenue. Excluding the impact of the previously noted $100 million in sales that shifted from Q4 2025 to early 2026 as a result of rough fiscal year alignment, our international segment growth was flat for the quarter.
接著看本季的國際事業部,營收以報告基礎成長17%,以有機營運基礎成長10%,營收達11億美元。若排除先前提及因會計年度對齊不佳而使1億美元銷售自2025年第四季移轉至2026年初的影響,我們國際事業部本季成長為持平。
International companion animal reported $654 million in sales, growing 7%. The competitive and macroeconomic headwinds we have seen in the US do exist in parts of our international business, but are largely concentrated in developed markets where conditions more closely resemble the US environment.
國際伴侶動物業務銷售額為6.54億美元,成長7%。我們在美國所見的競爭與總體經濟逆風,在部分國際業務中也存在,但主要集中於已開發市場,因其環境更接近美國。
In many of our emerging markets, where the standard of care is still maturing, we believe that meaningful market extension opportunities remain, and that distinction is evident in our international results this quarter.
在許多新興市場,醫療照護標準仍在成熟中,我們認為仍存在可觀的市場延伸機會,而這項差異在本季的國際業績中表現得相當明顯。
Our international Simparica franchise grew 14% on $147 million in sales. Simparica Trio posted sales of $76 million, growing 29%, driven by key account penetration in major markets and the benefit of our recent launch in Brazil. Simparica reported $71 million in revenue, which was flat on the quarter, impacted by conversion to TRIO in Brazil.
我們的國際Simparica系列銷售額為1.47億美元,成長14%。Simparica Trio銷售額為7,600萬美元,成長29%,主要受主要市場關鍵客戶滲透提升,以及近期在巴西上市的效益帶動。Simparica營收為7,100萬美元,本季持平,受到巴西轉換至TRIO的影響。
Partially offsetting our growth in the quarter, Key Dermatology posted $131 million in revenue internationally, down 5%. For Apoquel, similar to the US, competitive pressures and macro price sensitivity, which are more pronounced in developed markets where Apoquel has a larger presence, are having a compounding impact on sales.
部分抵銷本季成長的是,Key Dermatology在國際市場營收為1.31億美元,下滑5%。就Apoquel而言,與美國類似,競爭壓力與總體價格敏感度(在Apoquel佔比較高的已開發市場更為明顯)正對銷售造成疊加影響。
Similar to the US, ciderphone performance is holding up better than Apoquel. OA Pain mAbs posted $85 million in sales internationally, declining 2%. Librela reported $64 million in sales, down 7%.
與美國類似,ciderphone的表現比Apoquel更具韌性。OA疼痛mAbs在國際市場銷售額為8,500萬美元,下滑2%。Librela銷售額為6,400萬美元,下滑7%。
As Kristin noted, positive benefit-risk findings have helped strengthen our medical education effort around Librela, and we have seen a meaningful improvement in our conversations with veterinarians. Valencia grew 10% from $21 million in sales. Additionally, our international small animal vaccines products were 13% in the quarter, driven by increased usage of [Felavax] in China.
如Kristin所提到,正向的效益—風險(benefit-risk)研究結果有助於強化我們圍繞Librela的醫學教育推廣,我們也看到與獸醫對話有顯著改善。Valencia在2,100萬美元銷售額的基礎上成長10%。此外,我們的國際小動物疫苗產品本季成長13%,主要由中國[Felavax]使用量增加所帶動。
International livestock contributed $495 million, with growth of 14%, with broad-based growth across all of our core species. We saw growth in cattle, swine, and poultry driven by disease outbreaks, commercial wins, especially in vaccines, and improved supply. In fish, we continue to benefit from improved pricing on our Morotella vaccine, as well as volume growth from market expansion into the Faroe Islands.
國際畜牧業務貢獻4.95億美元,成長14%,我們所有核心物種均呈現廣泛成長。我們在牛、豬與家禽均見到成長,主要由疾病爆發、商業勝出(尤其在疫苗方面)以及供應改善所驅動。在魚類方面,我們持續受惠於Morotella疫苗價格改善,以及市場擴張至法羅群島帶來的銷量成長。
Now, let's move down to P&L. Adjusted gross margins of 71.8% declined approximately 10 basis points on a reported basis. Foreign exchange had an unfavorable impact of approximately 150 basis points. Excluding FX, we saw a 140 basis point improvement in margins due to benefit from price and lower manufacturing costs, partially offset by product and geographical mix.
接下來看損益表(P&L)。調整後毛利率為71.8%,以報告基礎約下降10個基點。外匯帶來約150個基點的不利影響。若排除外匯影響,我們看到毛利率改善140個基點,主要受惠於價格效益與製造成本下降,但部分被產品與地理組合所抵銷。
Adjusted operating expenses increased by 3% operationally due to higher compensation-related expenses, as well as increased freight and logistics costs. Adjusted net income grew 1%. Adjusted diluted EPS grew 7%, including a 3% benefit from our convertible debt-funded share repurchases.
調整後營業費用以營運基礎增加3%,主因為薪酬相關費用上升,以及運輸與物流成本增加。調整後淨利成長1%。調整後稀釋每股盈餘(EPS)成長7%,其中包含我們以可轉換公司債融資進行庫藏股回購所帶來的3%效益。
Now, moving on to guidance for the full year 2026. Our updated guidance is reflective of the current operating environment, as well as the presentation of our financials on an online fiscal calendar basis. Foreign exchange rates used in our guidance are as of late April.
接著談2026年全年指引。我們更新後的指引反映目前的營運環境,以及我們以線上財務日曆(online fiscal calendar)基礎呈列財務報表的方式。指引所採用的外匯匯率為4月底的水準。
We are revising our full-year revenue guidance to a range of $9.68 billion to $9.96 billion, with growth of 2% to 5% based on the current operating environment. It is worth noting that our fiscal year alignment was anticipated to provide approximately 200 to 250 basis points of tailwind to full-year revenue growth.
我們將全年營收指引修訂為96.8億至99.6億美元區間,在目前營運環境下對應成長2%至5%。值得注意的是,我們的會計年度對齊原預期可為全年營收成長帶來約200至250個基點的順風。
However, the challenging operating environment we experienced in Q1 and the expectations that carries for the remainder of the year more than offset that contribution. We do now expect adjusted net income to be in the range of $2.87 billion to $2.95 billion, with growth of 2% to 6%, reflective of the comprehensive cost and productivity programs Kristin mentioned earlier.
然而,我們在第一季所經歷的嚴峻營運環境,以及其對今年剩餘期間的預期影響,已超過並抵銷上述貢獻。我們目前預期調整後淨利將落在28.7億至29.5億美元區間,成長2%至6%,反映Kristin先前提到的全面成本與生產力計畫。
Finally, we are updating our reported diluted and adjusted diluted EPS guidance ranges to $6.35 to $6.50 and $6.85 to $7, respectively.
最後,我們更新報告稀釋與調整後稀釋EPS指引區間,分別為6.35至6.50美元,以及6.85至7.00美元。
While Q1 reflected a more challenging environment than we anticipated, particularly in US Companion animal, where the convergence of price sensitivity lowered, cleaning traffic, and intensified competition was more pronounced than expected.
雖然第一季反映的環境比我們預期更具挑戰,尤其在美國伴侶動物業務方面,價格敏感度上升、診所來客量下滑,以及競爭加劇的匯聚效應比預期更為明顯。
Our path forward is clear. We are taking decisive action to sharpen commercial execution and drive cost to support. Looking ahead, while we have appropriately reflected the near-term environment in our updated guidance, we remain confident in the underlying strength of our diversified portfolio and our ability to deliver the next cycle of renovation-driven growth in the years ahead. We remain committed to delivering long-term value for our shareholders.
我們前進的路徑很清楚。我們正採取果斷行動,以強化商業執行並推動成本支撐。展望未來,雖然我們已在更新後的指引中適當反映短期環境,我們仍對多元化產品組合的基本韌性,以及未來數年交付下一輪由創新驅動的成長週期之能力充滿信心。我們仍致力於為股東創造長期價值。
Now, I'll hand things back to the operator for your questions. Operator.
現在,我把時間交還給接線員,進行提問。接線員。
Operator
Operator
(Operator Instructions) Michael Ryskin, with Bank of America. Your line is open.
(接線員指示)美國銀行(Bank of America)的Michael Ryskin。您的線路已開通。
Michael Ryskin - Analyst
Michael Ryskin - Analyst
I'm going to throw a couple in here real quick. So one, Kristin, for you, just maybe a high-level, big-picture one. From what we see in the market, competition appears to still be at a relatively early point. We think it's only going to get worse from here. You've got a number of competing products that are still early in the launch cycle or haven't even launched yet at all. And with this increased competitive landscape, the macro consumer pressures.
我這邊很快丟幾個問題。第一個,Kristin,給你一個比較高層、宏觀的問題。從我們在市場上看到的情況,競爭似乎仍處於相對早期階段。我們認為接下來只會更嚴峻。你們面臨多個競品仍在上市初期,甚至尚未上市。在競爭版圖擴大之下,以及總體消費者壓力……
We think that's going to persist for some time, maybe as much as one or two years, if not longer. So when you talk about working through the challenges you're seeing, you call out pipeline innovation as an offset, from what we can tell, some of the bigger product launches you have are still a couple of years out. So what can you specifically do more in the near term to turn the ship around in the face of this growing competitive pressure and the consumer challenges? And then if I could squeeze in a second one real quick more for Wetteny. The math is a little bit messy given the calendarization impact, maybe bear with me, but you called out the 200-250 dips impact from calendar for once you specifically, you did one, you did zero organic.
我們認為這種情況將會持續一段時間,可能長達一到兩年,甚至更久。因此,當你談到如何應對你們所看到的挑戰時,你提到以研發管線創新作為抵消;但就我們所知,你們一些較大型的產品上市仍要再等上幾年。那麼,面對日益加劇的競爭壓力與消費者端的挑戰,短期內你們具體還能做些什麼來扭轉局面?另外,如果我能再快速追問第二個問題,主要是問 Wetteny。由於曆法調整的影響,計算有點複雜,請你包涵;但你提到曆法對你們的影響是 200-250 個基點,而就你們本身而言,你們做了一個,你們做了零的有機(成長)。
Under the new math, under the old calendar, maybe that comes out to something like down four or down five, given the $100 million benefit. And if you're guiding to something like low-single to mid-single-digit growth for the full year, that seems like a pretty aggressive ramp. You've got easier comps in the second-half. You do have the 4Q benefits in the calendar switch. But can you just bridge that for us? Is there anything else to factor in that'll get you to that full-year number after this 1Q print? Thanks.
在新的算法下、在舊的曆法下,考慮到 1 億美元的利多,可能會變成大約下滑 4% 或下滑 5%。而如果你們對全年給出的指引是低個位數到中個位數的成長,那看起來是一個相當激進的爬坡。你們在下半年有較容易的比較基期。你們也確實會在第四季因曆法切換而受益。但你能否幫我們把這之間的橋接講清楚?在第一季這個結果之後,還有沒有其他需要納入考量、才能讓你們達到全年那個數字?謝謝。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Thanks, Mike. I'll start, and then Wetteny can build on your second question. Especially what we saw in the quarter was sort of the economic and sustained price increases that the pet owner has experienced in the clinic. This has obviously made them much more sensitive, but also, as you saw, led to a decrease in vet visits, especially in some of the key therapeutic areas that we're in, such as, paras, OA Pain, derm, et cetera. And I think this combined with an increase in price-driven competition, as, people. Saw the pressure that the pet owners on. I think you saw more promotions and more price competition there. And really, what that happened is that the market did not grow.
謝謝,Mike。我先回答,然後 Wetteny 可以補充你的第二個問題。本季我們看到的,主要是寵物主人在診所端所承受的經濟壓力與持續性的價格上漲。這顯然讓他們變得更為敏感;同時,如你所見,也導致獸醫就診次數下降,尤其是在我們所處的一些關鍵治療領域,例如寄生蟲、骨關節炎疼痛、皮膚科等。我認為這再加上以價格驅動的競爭加劇,因為人們……看到了寵物主人所承受的壓力。我想你也看到更多促銷與更激烈的價格競爭。而其結果就是,市場並沒有成長。
Historically, as you've seen over the last few years, when we had competition increasing in Paris, the market grew. And I think what I think changes is that with new competition, we didn't see that market grow. I think the difference I think we might have with you as to what we see in the future is we are seeing positive trends. As Wetten and I mentioned in our remarks. If you look at Paris, for example, we have actually gained share from the end of last year into this year. And we ended the quarter, as we mentioned, pretty close to where we were last year before the competition entered.
過去幾年你也看到,歷史上當我們在寄生蟲領域的競爭加劇時,市場是成長的。而我認為這次的變化在於:即使有新的競爭者進入,我們並沒有看到市場成長。我想我們與你對未來的看法可能不同之處在於:我們正在看到正向趨勢。正如 Wetteny 和我在發言中提到的。以寄生蟲為例,從去年底到今年,我們其實是提升了市占。而且如我們所提到的,本季結束時,我們的水準已相當接近去年在競爭者進入之前的水準。
So again, our focus will be on expanding the markets. But I think if you look at Paris, we're pleased at the progress that we continue to make there. We're also pleased that with Librela, we saw stabilization of that product. As we look to the rest of the year, we continue to believe we can return that product to growth overall. Obviously, in the first half of the year, we have some tough comparable periods, but I think as we move through the year, we'll continue to gain share there and to grow.
所以再次強調,我們的重點會放在擴大市場。但如果你看寄生蟲這一塊,我們對持續取得的進展感到滿意。我們也很高興看到 Librela 這個產品趨於穩定。展望今年剩餘時間,我們仍相信整體而言可以讓該產品恢復成長。顯然,上半年我們會面臨一些較艱難的比較基期,但我認為隨著年度推進,我們會持續在那裡提升市占並帶動成長。
Obviously, in Durham, we do have to continue to see new entrants, but we think we have a strong differentiated portfolio there. We're also excited to be adding long-acting CITA point as we look to the end of the year, and look, we are sharpening our focus. On execution of our commercial strategy. We're going to continue with veterinarians, leveraging the broad portfolio that we have and providing them integrated solutions to help capture share.
顯然,在皮膚科領域,我們確實還會持續看到新進者,但我們認為我們在那裡擁有強而有力、具差異化的產品組合。我們也很期待在接近年底時加入長效型 CITA point,而且你看,我們正在更聚焦。在商業策略的執行上。我們將持續與獸醫合作,運用我們廣泛的產品組合,並提供整合式解決方案來協助取得市占。
We're going to focus with pet owners, as I mentioned, leveraging DTC to help broaden that market, but importantly, focus on affordability, which is clearly a major issue for them at the point of sale through loyalty and some affordability options we're providing. We'll also focus as well at retail and home delivery to optimize access there.
我們也會如我所提到的,聚焦寵物主人端,運用 DTC(直接面向消費者)來協助擴大市場;但更重要的是,聚焦可負擔性——這顯然是他們在銷售端點的一個重大議題——透過忠誠計畫以及我們提供的一些可負擔性選項來改善。我們也會同樣聚焦零售與到府配送,以優化那裡的可及性。
So we think we've got a strong portfolio there that we can continue to build on. And I also don't want to undermine the strength we saw in diagnostics and livestock in the US. And across the globe. But with that, Wetteny, I'll turn it over to you.
因此我們認為我們在那裡有一個強健的產品組合,能夠持續在此基礎上發展。我也不想淡化我們在診斷業務與美國的畜牧業務所看到的強勁表現。以及在全球各地。不過接下來,Wetteny,我把時間交給你。
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Yeah, my thought -- the first thing to really note here, and importantly, is that our initial guidance already contemplated some first half to second-half dynamics. Now, clearly, the quarter ended up.
是的,我的看法——首先真正需要注意、而且很重要的是,我們最初的指引其實已經納入了上半年到下半年的一些動態差異。當然,本季最終的結果……
Below our expectations, but this dynamic around the persistence of competition and macro was something we contemplated and we are seeing, and so we expect those to continue in the guidance that we give today. But to the point. Kristin just raised, we do see stabilization in a number of areas, including Librela. With our already paying franchises, we are launching our long-acting products in a couple of markets, and a few markets here in the quarter as well, and across our Symparica franchise and so forth. Now, as we noted in our prepared commentary, you heard that this end-market demand softness also caused.
低於我們的預期,但競爭與總體環境持續的這種動態是我們原本就考量到、也正在看到的,因此我們預期這些因素會在我們今天給出的指引中持續存在。但回到 Kristin 剛剛提出的重點,我們確實在多個領域看到趨於穩定,包括 Librela。在我們既有的寄生蟲產品線方面,我們正在幾個市場推出長效型產品,本季也在少數市場推出,並且在我們的 Symparica 產品線等方面亦是如此。另外,如同我們在事先準備的說明中提到的,你也聽到終端市場需求疲弱也造成了……採購模式在本季成為我們的逆風。
Purchasing patterns to be a headwind for us in the quarter. But we ended the quarter at a level that we believe is also normalized for how we go from here versus being a headwind given they ordered less to do in the quarter than they were shipping out to clinics. So with those and the actions that we are taking, we have widened the range and the guidance given we do see remaining uncertainty in the markets that we operate, but we're also executing against those, hence the guidance that we have issued today.
但本季結束時,我們的水位已達到我們認為從此往後較為正常化的水準,而不至於因為他們在本季下單少於其出貨到診所的量而持續形成逆風。因此,綜合這些因素以及我們正在採取的行動,我們擴大了區間並給出指引,因為我們確實仍看到我們所營運市場存在不確定性,但我們也正在針對這些因素執行對策,因此才有我們今天發布的指引。
Operator
Operator
Erin Wright, Morgan Stanley.
Erin Wright,摩根士丹利。
Erin Wright - Equity Analyst
Erin Wright - Equity Analyst
I want to dig into that a little bit more. So what does guidance imply now for the quarterly progression for companion animal, I guess, given the implied ramp here? Even backing out the easy realignment comp in the fourth quarter, which is about a point, like.
我想再深入一點。那麼,考量到這裡隱含的爬坡幅度,指引現在對伴侶動物業務的季度走勢意味著什麼?即使把第四季較容易的重分類比較基期(大約一個點)剔除,像是……
Are you baking in some distributor or retail then restock? Is that what you're implying after the destock? And why is that just given the increasing competition? And how much of a headwind was that in the quarter? And were there significant changes in purchasing patterns, I guess, at retail as well? You mentioned script denials. Can you talk a little bit more about that and that's now going back to their typical conflicts of interest there with online scripts and denying scripts there? And can you clarify a little bit more about what we're lapping here. From last year in terms of stocking and destocking dynamics, because I want to make sure just we're aware, given some of the unforeseen dynamics in the current quarter on stocking and destocking dynamics and how much you're leveraging the channel.
你們是否在假設經銷商或零售端會補庫存?也就是說,在去庫存之後,你們所暗示的是補庫存嗎?但在競爭加劇的情況下,為什麼會這樣?而這在本季造成了多大的逆風?另外,我想問零售端的採購模式是否也有顯著變化?你提到處方被拒(script denials)。你能否再多談一點?這是否又回到他們在網路處方上典型的利益衝突、以及在那裡拒絕處方的情況?另外,你能否更清楚說明一下我們正在對比去年的哪些因素,就庫存與去庫存的動態而言,因為我想確認我們有掌握到——鑑於本季在庫存/去庫存動態上出現一些未預期的變化——以及你們在多大程度上是在倚賴通路。
And I guess one bigger picture question just on guidance as well, you talk about the 200 basis point benefit from the accounting change. Now embedded in the guide. I just want to confirm one point of that will not recur in 2027, right? So, as we think about 2027 and beyond, how do you mitigate that and when could we get back to, your typical 68% operational revenue growth? Thanks.
我想再問一個較宏觀、同樣關於指引的問題:你們提到會計變更帶來200個基點的利多。現在這已經內嵌在指引裡了。我只是想確認其中有一部分在2027年不會再發生,對吧?所以,當我們思考2027年及之後時,你們要如何緩解這個影響?以及何時能回到你們典型的68%營運收入成長?謝謝。
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Sure, Aaron. Look, with particular unpacking the guidance, starting with companion animal, then we'll get to your bigger picture question in terms of comps going into 2027. We are not embedding an assumption that inventory picks up in terms of the level of inventory that is in distribution. We typically don't do that. As you may recall, you've been around with us for a long time.
當然,Aaron。你看,就指引的拆解而言,我們先從伴侶動物開始,然後再回到你關於進入2027年的比較基期(comps)的宏觀問題。我們並沒有在假設通路端的庫存水位會回升、也就是分銷體系中的庫存量會增加。我們通常不會這麼做。如你所記得的,你跟我們很久了。
In 2023, we saw quite a step down in terms of level of inventory that distributors take. We have not assumed that those would come back into the channel, and they have not. We've been operating at a range that is well below where we were pre-2023, and within that range, we're now operating at the low end of that. That new range if you follow as we exit the first quarter of '26.
在2023年,我們看到分銷商持有的庫存水位出現相當明顯的下滑。我們沒有假設那些庫存會回到通路中,而事實上也沒有回來。我們一直在一個遠低於2023年前水準的區間內運作,而在這個區間裡,我們目前正處於偏低端。如果你追蹤的話,這就是我們在26年第一季結束時所處的新區間。
So we are not baking in some rebound in that. It is reflective of what the end market demand has been, and it's reflected in the performance that we shared today with respect across our key franchises. And so what we are embedding here, and by the way, we are also assuming headwinds related to competition that is to launch and continued pressure from in terms of what we're seeing.
所以我們沒有把某種庫存反彈納入假設。這反映了終端市場需求的實際情況,也反映在我們今天就各主要產品線所分享的表現上。因此我們在此內嵌的內容——順帶一提——也包含我們假設將面臨與即將上市的競品相關的不利因素,以及我們所看到的持續壓力。
From a competitive and macro perspective. And so the script denials have been an impact as we look at retail. Retail continued to grow faster than the clinic, though, but not at the rate that it had been over the last couple of years. If you go back to last year and the year before, you were seeing retail growth somewhere in the 25% to 30% range. That growth rate in retail is in the low double-digits as we look at this quarter, somewhere in the 10% also range.
從競爭與總體環境的角度來看。因此,處方被拒(script denials)在我們觀察零售端時確實帶來影響。不過零售端仍然比診所端成長更快,只是成長速度不如過去幾年。如果回到去年與前年,你會看到零售成長大約在25%到30%的區間。而就本季來看,零售的成長率落在低雙位數,大約在10%左右。
In detail. So clearly, a step down, and part of that is what we're seeing in terms of script analysis. Again, we're not assuming those necessarily come back. It's really the actions that we're taking to drive commercial execution as well as the easier comps that we face as we get into the back half of the year that's playing here. Now, we won't get ahead in terms of what 20-2007 looks like. Clearly, the 200-350 basis points that we're talking about is a combination of coming into Q1 and then what is the Q4 comp is versus the prior year.
更細節地說。所以很明顯是下了一個台階,其中一部分就是我們在處方分析(script analysis)方面所看到的情況。同樣地,我們並不假設那些一定會回來。這更多是我們正在採取的行動,以推動商業執行力,以及當我們進入下半年時所面臨較容易的比較基期在發揮作用。至於2027年會是什麼樣子,我們不會搶先下結論。很明顯,我們所談的200到350個基點,是由第一季的進入效應,以及第四季相對於前一年的比較基期所共同構成。
And so that will clearly be a headwind when you go into 2027, all sales being equal. However, we are executing to what the market is showing, both in the top-line to drive performance there, as well as the bottom line, which is why you see a guidance that shows leverage through the P&L down to the bottom line.
因此,當你進入2027年時,在其他銷售條件相同的情況下,這顯然會成為逆風。不過,我們會依據市場所呈現的情況來執行:一方面在營收端推動表現,另一方面也在獲利端著力;這也是為什麼你會看到我們的指引顯示,損益表(P&L)一路往下到最終獲利都有槓桿效益。
Operator
Operator
Brandon Vazquez, William Blair.
Brandon Vazquez,William Blair。
Brandon Vazquez - Analyst
Brandon Vazquez - Analyst
Hey, thanks for taking the question. Maybe I can start with a high-level question. Kristin, you were talking a lot about kind of the headwinds you guys are seeing from a macro perspective, right? Let's just ignore some of the competitive and company-specific issues, but. We're talking about price being a lever here. We're talking about markets not expanding.
嗨,謝謝讓我提問。也許我先從一個高層次的問題開始。Kristin,你談了很多你們從總體環境角度看到的逆風,對吧?先暫時忽略一些競爭與公司特定的問題。但我們談到價格成為一個槓桿。我們談到市場沒有擴張。
We're talking about more competition, even generic competition. These are all very uncharacteristic, I think, of what this market historically used to be. It used to be resilient. It used to take price. It used to not really have a lot of generics, and it used to be powered by brand. And so the question being, it feels like what you're describing is entering a new world. This market, one that maybe is less durable and less attractive for zoetis. Is that true? What is, I mean, clearly you guys are assuming something improves. What is it that's giving you hope that this kind of reverses back into the old animal health market we used to know?
我們談到更多競爭,甚至是學名藥競爭。我認為這些都非常不符合這個市場過去的歷史特徵。它過去很有韌性。它過去能夠承受漲價。它過去其實沒有太多學名藥,而且主要由品牌驅動。所以問題是:你描述的情況讓人感覺像是進入了一個新世界——一個可能對Zoetis而言較不耐久、也較不具吸引力的市場。這是真的嗎?我的意思是,很明顯你們假設某些事情會改善。是什麼讓你們有信心,這會逆轉並回到我們過去熟悉的那種動物保健市場?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. I mean, for starters, I'd say, look, the demand for veterinary care remains structurally very strong, given the importance of the human-animal bond and the large number of untreated populations.
當然。我想首先我會說,獸醫照護的需求在結構上仍然非常強勁,原因在於人寵連結的重要性,以及仍有大量尚未被治療的族群。
That's clear. If you look, and as I mentioned in my prepared remarks, we're continuing to see strength in urgent care, and we're continuing to see strength in diagnostics and areas like that, which says to me, the pet owner still wants to get care. I think they're in a period where they're a little bit struggling with the price increases over the last few years.
這點很明確。如果你看——正如我在事先準備的發言中提到——我們持續看到急診照護(urgent care)維持強勁,我們也持續看到診斷(diagnostics)等領域的強勁表現,這讓我認為飼主仍然想要讓寵物接受照護。我認為他們正處在一個階段,對過去幾年的價格上漲感到有些吃力。
Ultimately, believe that will stabilize. I think that clinics are really trying to address that and trying to get the pet owners back in. As us and others have mentioned, we saw about 3% growth of revenue in the clinic, but that was all driven and continued by price, with clinic visits down about 3%. Ultimately, that will stabilize. We firmly believe that.
我最終相信這會趨於穩定。我認為診所也正在努力處理這個問題,並試圖讓飼主回到診所。正如我們與其他人提到的,我們看到診所端營收約成長3%,但完全是由價格所驅動並延續,而診所就診次數約下降3%。最終這會穩定下來。我們對此深信不疑。
We're also really optimistic, as we've seen, of the sequential trends we've seen in areas like OA Pain and in Paris. We think that the strength of our portfolio, the differentiation, the innovation we provide, will endure. I don't think we're moving to a world of generics. We are not expecting generics in any of our key categories. We're not expecting it in Derm, we're not expecting it in Pain or in Paris in the near term.
我們也非常樂觀,因為我們看到在像是OA疼痛(骨關節炎疼痛)以及Paris等領域的連續性趨勢改善。我們認為我們產品組合的強度、差異化以及我們提供的創新將會持續。我不認為我們正在走向一個學名藥的世界。我們不預期在任何關鍵類別會出現學名藥。短期內,我們不預期皮膚科(Derm)會有,也不預期疼痛(Pain)或Paris會有。
So for the next, many years, we will not see that. There's certainly, as we saw in, Cerenia and Convenia, which are blockbuster products, but not ones we talk about. We did see some increased competition from generics there. The competition we see today is not generic in our major therapeutic areas. It's products that, have launched that we've been in categories we've been in for a while. We ultimately believe some of these price-driven promotions will stabilize over time.
所以在接下來很多年,我們都不會看到那種情況。當然,正如我們在Cerenia與Convenia上看到的——它們是重磅產品,但不是我們常談的那些——我們確實看到那裡的學名藥競爭有所增加。但我們今天在主要治療領域看到的競爭並不是學名藥。而是一些已上市的產品——我們在那些類別已經耕耘了一段時間。我們最終相信,部分由價格驅動的促銷活動會隨時間推移而趨於穩定。
And we also believe the differentiation I think we have with our portfolio, the strength of our brand, and importantly, the strength of the service we provide veterinarians will endure. So, no, I don't. Don't see it the way you do. I think innovation matters. I think the service you provide matters. And I think ultimately, given the strength of the human-animal bond and the structural demand for veterinary care, that this will stabilize over time.
我們也相信,我們產品組合的差異化、品牌的強度,以及更重要的是我們為獸醫提供的服務實力,將會持續。所以,不,我不——不會像你那樣看待。我認為創新很重要。我認為你提供的服務很重要。而且我認為,鑑於人寵連結的強度以及獸醫照護的結構性需求,這些情況會隨時間推移而穩定下來。
Operator
Operator
Chris Schott, J.P. Morgan.
Chris Schott,摩根大通(J.P. Morgan)。
Christopher Schott - Analyst
Christopher Schott - Analyst
Great. Thanks for the questions. Just two for me. Can you just comment on your latest assumption around pricing this year, given some of the comments you're making around the promotion activity you're seeing from your competitors? Is that something you're reacting to on price on your side, or is that more share loss on those near-term dynamics?
很好。謝謝提問。我這邊只有兩個問題。鑑於你提到看到競爭對手的促銷活動,你能否評論一下你們對今年定價的最新假設?你們這邊是否也在價格上做出反應,還是說這更多是短期動態造成的市占流失?
And the second question, sorry if I missed this in the remarks, but when I think about US Companion growth and what's reflected in guidance. Can you just talk a little bit about how we should be thinking about growth for this year? I know you're assuming recovery from the down 12% this quarter, but this is a business we should assume is down this year with livestock and some of the international dynamics driving growth or do you think this is a business that can kind of get back to flat or growing as we go through the year?
第二個問題,如果我在你們的發言中漏聽了先說抱歉,但當我思考美國伴侶動物(US Companion)的成長以及指引中反映的內容時。你能否多談一點我們應該如何看待今年的成長?我知道你們假設會從本季下滑12%中復甦,但這是否意味著在牲畜以及一些國際動態帶動成長的情況下,這個業務今年仍應假設是下滑的;或者你認為這個業務在今年推進過程中可以回到持平甚至成長?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure, I'll start on the price one, and then Wetteny can take the guide. As we've always said, we are not planning to complete, to compete, through price as our main strategy. Our focus, as always, will remain on our differentiated portfolio, the breadth of it, the service we provide in execution. We are a premium, innovative brand, and that is not going to change.
當然,我先回答價格的問題,然後由Wetteny來談指引。正如我們一直說的,我們不打算以價格作為主要策略來競爭。我們一如既往的重點會放在我們具差異化的產品組合、其廣度,以及我們在執行上提供的服務。我們是一個高端、創新的品牌,這點不會改變。
We did take price, as you saw in the quarter. I think we can continue and what we can talk, where it is relative to historic price challenges. Obviously, in areas where we've seen generic competition, we have taken selective price actions there. We'll obviously continue to leverage promotions. But our priority remains innovation, differentiation, and service to our customers. And we continue to believe we can take price, albeit maybe at lower levels of right now, given the challenges we're facing right now. But I'll let you put that into. And also talk about the impact on the guy.
我們確實如你在本季所見進行了提價。我認為我們可以持續,也可以談談相對於歷史上的定價挑戰目前處於什麼位置。顯然,在我們看到學名藥競爭的領域,我們已在那裡採取了選擇性的價格措施。我們也會持續運用促銷。但我們的優先事項仍是創新、差異化,以及對客戶的服務。我們仍然相信我們可以提價,只是考量目前面臨的挑戰,幅度可能會比現在更低一些。但我讓你把這些納入。也談談對那位(guy)的影響。
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Chris, as we don't typically provide guidance down to the species, but I would share a couple of things that I think might be helpful for you. Just keep in mind, we are running a global diversification business with companion animals both in the US and outside the US, and in the quarter, our international segment companion animal grew 7%.
Chris,由於我們通常不會把指引細分到物種層級,但我可以分享幾點我認為對你有幫助的資訊。請記住,我們經營的是全球多元化業務,伴侶動物不僅在美國,也在美國以外;而在本季,我們國際事業部的伴侶動物成長了7%。
I would add also, given the dynamics that we described and the headwinds of those created in the quarter, including how distributors' order pattern and retail had a more pronounced effect on the first quarter. We do see stabilization across companion animal as we go with the key franchises. And what we're saying now is we expect our key franchises to grow in the low to mid-single-digits, which is a step down from what we said.
我也想補充,鑑於我們所描述的動態以及本季形成的逆風,包括經銷商的訂貨模式,以及零售端對第一季的影響更為明顯。隨著我們推進關鍵產品線(key franchises),我們確實看到伴侶動物業務趨於穩定。我們現在的說法是,預期關鍵產品線將以低到中個位數成長,這比我們先前所說的有所下調。
When we initially issued guidance. And so when you take all that into consideration, yes, we do expect livestock to continue to drive momentum here. I would put livestock in the mid to high single-digit growth range for the year, but the balance would be growth across without getting into specifics on guidance.
在我們最初發布指引時。因此,綜合考量上述因素,是的,我們預期牲畜業務將持續帶動動能。我會把牲畜今年的成長放在中到高個位數區間,但其餘部分將是廣泛的成長,而不進一步細談指引細節。
Operator
Operator
John Block, Stifel.
John Block,Stifel。
Jonathan Block - Analyst
Jonathan Block - Analyst
Maybe just the first one, Wetteny, I believe you said the channels now normalized. Do you think that US Pet Health numbers surprised everyone? So is there a way of calling out the impact in 1Q26 from the channel, what that was specific to US Pet Health?
第一個問題,Wetteny,我記得你說通路現在已經正常化。你認為美國寵物健康(US Pet Health)的數字讓大家都感到意外嗎?那麼,有沒有辦法點出26財年第一季通路因素的影響,尤其是對美國寵物健康的具體影響是多少?
And then, Kristin, just to back up at a higher level, I'm just trying to dig in on the competitive response, and maybe I was a little confused. So. Is anything changing from Zoetis among your approach to call it the atopic derm or the trio franchises regarding price? If it's not sort of unilateral, are there any targeted promotions or no, because it seemed like you acknowledge the consumer wants.
然後,Kristin,回到更高層次,我想深入了解競爭對手的反應,可能我有點困惑。所以。Zoetis在異位性皮膚炎(atopic derm)或trio產品線在定價方面的做法,有任何改變嗎?如果不是單方面的調整,是否有任何針對性的促銷?還是沒有?因為聽起來你們承認消費者想要——
A cheaper alternative or is looking for that and then I was a bit confused if Zoetis is pivoting there and trying to deliver on that or just really focus on the bundling and the services. Thanks.
更便宜的替代方案,或正在尋找那樣的選項;因此我有點困惑,Zoetis是否在那裡轉向、試圖滿足這個需求,還是只是更專注於組合銷售(bundling)與服務。謝謝。
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Yeah, perhaps, John, I'll take. The normalization point around inventory. Clearly, it is, I would say, difficult to separate out the macro and the soft in-market demand versus what the patterns are and what distributors and retailers did in terms of adjustments. Again, they ordered less. From us than they were shipping out to customers, given the software in-market demand and promotions that did not execute to the level that we expected coming into the year, right?
是的,John,或許我來回答。關於庫存正常化這點。很明顯地,我會說很難把總體環境(macro)與終端市場需求疲軟,和經銷商與零售商在調整上所做的行為模式完全切割開來。再說一次,他們向我們下的訂單少於他們出貨給客戶的量,原因在於終端市場需求疲軟,以及促銷執行未達到我們年初預期的水準,對吧?
And so that certainly had a pronounced impact, but I would put that back to the macro and competitive dynamics that we're seeing and the impact it has in terms of in-market demand.
因此那確實帶來了更明顯的影響,但我會把它歸因於我們看到的總體與競爭動態,以及其對終端市場需求所造成的影響。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure, John, I'll build up the second part of your question. My point is we're not overall lowering our list price and products. We continue to run promos as we always have seasonal promos for paras.
好的,John,我來延伸回答你問題的第二部分。我的重點是,我們整體上並沒有下調我們的牌價(list price)與產品價格。我們仍像以往一樣進行促銷,例如針對驅蟲(paras)的季節性促銷。
We can do cross-portfolio promos in the United States, leveraging both derm and other categories. But I think what I was really focusing on is addressing the affordability issue, which is actually a pet owner. That's not what we sell into the vet. It's the pet owner at point of sale. We've always had loyalty programs, as but those loyalty programs are you scan your receipt and then you get. At a cash back part to spend later. Given the affordability issue that is more urgent, we're looking at more point-to-sale loyalty programs, more ability to deal at point-of-sale with the challenges the pet owner may be having economically.
我們也可以在美國做跨產品組合的促銷,結合皮膚科(derm)與其他類別。但我真正聚焦的是解決可負擔性(affordability)問題,而這其實是寵物主人的問題。我們賣給獸醫的不是這個。在銷售點(point of sale)面對的是寵物主人。我們一直都有忠誠度計畫,但那些忠誠度計畫是你掃描收據,然後你會得到——一部分現金回饋,之後再用來消費。鑑於可負擔性問題更為迫切,我們正在研究更多銷售點即時的忠誠度計畫,讓我們能在銷售點更直接地處理寵物主人在經濟上可能面臨的挑戰。
So our real focus there is not as much on the vet, but on the pet owner issue. We have these programs today, but as I said, we're looking to alter them to make sure we can do that more at point-of-sale versus just over time, where they can use it, in a month or two, et cetera. We're really trying to make sure we address that with. In the United States and across the globe.
所以我們在這裡的重點與其說在獸醫端,不如說是在寵物主人的議題上。我們今天就有這些計畫,但如我所說,我們正在考慮調整,確保我們能更多在銷售點即時提供,而不是隨時間累積,讓他們在一兩個月後等等才使用。我們真的在努力確保能解決這個問題——在美國以及全球各地。
Operator
Operator
Steve dechert, KeyBanc.
Steve Dechert,KeyBanc。
Steven Dechert - Equity Analyst
Steven Dechert - Equity Analyst
I guess just first, on price sensitivity, is that still limited to the Gen Z and millennial age groups, or does that spread more into other age groups now? And then just on Lenivia, as you move closer to US launch next year, how tied is the performance of that drug? Do you expect it to be tied to Labrela just or or should we view those as two completely separate products?
我想先問,關於價格敏感度,這是否仍然只限於Z世代與千禧世代,還是現在已擴散到其他年齡層?另外關於Lenivia,隨著你們接近明年在美國上市,這個藥物的表現與Labrela的關聯程度有多高?你預期它會與Labrela綁在一起,還是我們應該把它們視為兩個完全獨立的產品?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. So, I'll start with your question with regards to Linidia. With regards to Linidia, we did get approval in certain markets in the EU and in Canada, and we just launched that product. So, we look forward to having more information on how that launch is going as we go into the next quarter. As we talked about, this is not long-acting liberlla. We think the efforts, the multi-pronged strategy we've been executing across OA Pain, really focusing on awareness that treating OA Pain is a serious. Is important, making sure we spend time with vets and specialists understanding OA Pain will continue to be important.
好的。那我先從你關於Linidia的問題開始。就Linidia而言,我們已在歐盟部分市場以及加拿大取得核准,並且剛剛上市。因此,隨著進入下一季,我們也期待能有更多資訊來了解這次上市的進展。如我們所談到的,這不是長效型的Librella。我們認為,我們在OA疼痛(OA Pain)領域所執行的多管齊下策略,特別是提升對治療OA疼痛重要性的認知——這是一個嚴肅的議題。很重要;並確保我們花時間與獸醫及專科醫師溝通、理解OA疼痛,將會持續很重要。
Also, making sure we share the science and the positive experience that many of our customers have and investing in that phase four research. We think building this understanding of OA Pain will be important as we launch long-acting. Certainly, that's what we're experiencing right now in certain markets in the EU and in Canada, and we think that long-acting provides, again, to the issue that pet owners are having. On just, convenience as well as affordability, a great new option. So we're excited for that.
此外,確保我們分享科學證據以及許多客戶的正面使用經驗,並投資於第四期研究。我們認為,在我們推出長效型產品之際,建立對 OA 疼痛的這種理解將會很重要。當然,這正是我們目前在歐盟某些市場以及加拿大所看到的情況;我們也認為,長效型產品再次回應了飼主所面臨的問題。就便利性以及可負擔性而言,這是一個很棒的新選擇。所以我們對此感到非常振奮。
I think you asked the second question with regards to demographics on Gen Z and millennials. I mean, I think affordability is more based on the economic situation that a pet owner is in. It's not just based on age, to be honest. So we're really targeting the affordability issue, not at generations, but just as pet owners overall who are facing those challenges.
我想你第二個問題是關於 Z 世代與千禧世代的人口統計。我的意思是,我認為可負擔性更多取決於飼主所處的經濟狀況。老實說,並不只是取決於年齡。因此我們真正鎖定的是可負擔性的議題,不是針對特定世代,而是針對整體面臨這些挑戰的飼主。
Operator
Operator
Navann Ty, BNP Paribas.
Navann Ty,法國巴黎銀行(BNP Paribas)。
Navann Ty - Analyst
Navann Ty - Analyst
Hi, thanks for taking my question. A follow-up on the pricing strategy. So you discussed the pricing against that price sensitivity. And I'm also curious of your pricing strategy to defend against the competitive pressure in derms, which is further intensifying, and also your pricing strategy for your upcoming innovation in renal oncology and cardiology that price sensitivity environment is maintained.
嗨,謝謝讓我提問。我想追問一下定價策略。你們談到在價格敏感度下的定價。我也想了解,你們在皮膚科(derms)領域面對競爭壓力(且正在進一步加劇)時的防禦性定價策略;以及在腎臟腫瘤與心臟科即將推出的創新產品上,在維持價格敏感環境下,你們的定價策略會是什麼?
And then I have a second question on Derm specifically, because we are seeing that the competitor has raised prices on the JAK, so would you say that the competition is now not only on price, but also some efficacy in frontline users?
另外我還有第二個問題,特別是關於皮膚科:因為我們看到競爭對手已調高 JAK 的價格,所以你會說現在競爭不僅在價格上,也在第一線使用者的療效上嗎?
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Sure, Nevon, I'll take your question on pricing strategy. And look, the way we approach pricing is always down to each market, each product, and what is the value that we're bringing and what is the competitive landscape at the time. And as Kristin referenced earlier, we now have an aggregate price expectation. This is not by product, of course, for the company that's in the 1% to 2% range when we started the year 2% to 3%, and we've been higher than it over the last couple of years. So clearly, we have adjusted our expectations, not getting down to. Specific pricing actions and strategy on a specific product for competitive reasons here on this call.
好的,Nevon,我來回答你關於定價策略的問題。你看,我們看待定價的方式一向是回到每個市場、每個產品,以及我們帶來的價值是什麼,還有當時的競爭態勢。正如 Kristin 先前提到的,我們現在有一個整體的價格預期。當然這不是按產品拆分;公司層級的預期在 1% 到 2% 的區間,而年初我們的預期是 2% 到 3%,且過去幾年我們一直高於這個水準。因此很明顯,我們已調整了預期,但不會在這裡進一步細談。在這通電話上,我們不會就特定產品、出於競爭原因的具體定價行動與策略做說明。
But certainly, we are taking those into consideration. And as we launch new products, we should do extensive market research on prior to launch. We, of course, will be looking at what is the value that we're bringing clinically. And what is the willingness to pay for that, which we continue to see sustaining across the industry. So that will be what we'll put into place.
但我們當然會把這些因素納入考量。而在推出新產品時,我們會在上市前進行大量的市場研究。我們當然會評估我們在臨床上帶來的價值是什麼,以及市場對此的支付意願;我們持續看到這在整個產業中仍具延續性。因此,這將是我們會採取並落實的做法。
In terms of competitors' prices, look, as you've said, historically, we've seen competitors come in with list prices that are somewhat slightly below where ours are, but with aggressive promotions initially to get the products embedded into clinics.
至於競爭對手的價格,你看,正如你所說,過去我們看到競爭對手進入市場時,標價通常會略低於我們的水準,但一開始會用更積極的促銷,讓產品更快被診所採用。
And so forth. So we've certainly seen that. The price in the market is translating to that lasting longer, I would say, than we've seen historically. But they are, in many instances, and including you referenced one, are raising prices well above where we're raising. It still remains that there's a gap between where our pricing is versus where theirs is, but it is closing in effect. And so we'll continue to monitor those, but also executing on our actions against those, including the grass and strength of our portfolio.
等等。所以我們確實看過這種情況。我會說,市場上的價格壓力持續的時間,比我們過去歷史上看到的更久。但在許多情況下——包括你提到的那一家——他們的漲價幅度遠高於我們的漲幅。目前我們的定價與他們之間仍然存在差距,但實際上正在縮小。因此我們會持續監測,同時也會執行我們的應對措施,包括我們產品組合的廣度與強度。
Operator
Operator
Daniel Clark, Leerink Partners.
Daniel Clark,Leerink Partners。
Daniel Clark - Equity Analyst
Daniel Clark - Equity Analyst
Great. Thank you. Also wanted to ask about the 2026 updated guide. How are you thinking about the macro and sort of competitive intensity as we head through the year? Should we expect similar levels of both as we saw on 1Q through the rest of the year? I guess how are you thinking about that? And then secondarily, I just wanted to quickly ask. How much did Derm grow ex-US. If we strip out any of the alignment impacts?
很好。謝謝。我也想問一下 2026 年更新後的指引。你們如何看待宏觀環境以及競爭強度在接下來一年中的走勢?我們是否應該預期,從第一季(1Q)到今年剩餘期間,兩者都會維持與第一季相近的水準?你們是怎麼思考的?另外第二個問題,我想快速問一下:如果剔除任何對齊(alignment)影響,皮膚科在美國以外(ex-US)的成長是多少?
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Sure. In terms of our expectations on the macro, we are expecting that to persist.
好的。就我們對宏觀環境的預期而言,我們預期這種狀況會持續。
And so we're not expecting a rebound nor a significant deterioration in terms of what the macro looks like. We've seen the impact that it has both in terms of in-market demand and then, therefore, directly impacts to where distributors and retailers are replenishing their inventory levels, which. A headwind for us. And so that's the answer on that one.
因此,我們不預期會出現反彈,也不預期宏觀環境會顯著惡化。我們已看到它帶來的影響,既包括終端市場需求(in-market demand),也因此直接影響到經銷商與零售商補貨其庫存水位的節奏,這。對我們而言是一項逆風。所以這題的回答是這樣。
In terms of TDRM and what the implications might be related to FYA, we have not broken those down to individual products to individual markets to be able to get to that level. We believe we've been very helpful in our comments, which is what the overall impact is and what we would have expected to be the guidance impact, which is around 200 to 250 basis points lift in our guidance and clearly given the performance we've seen. And the persistence that we're expecting in the macro and competitive dynamics, that has not come to fruition in the guidance that we're giving today.
至於 TDRM 以及可能與 FYA 相關的影響,我們尚未把它拆分到單一產品、單一市場的層級,因此無法提供那麼細的數字。我們認為我們在評論中已提供了很有幫助的資訊,也就是整體影響是什麼,以及我們原本預期對指引的影響——大約是讓我們的指引上調 200 到 250 個基點;而且很明顯,基於我們看到的表現,以及我們預期宏觀與競爭動態將持續存在,這並未在我們今天給出的指引中實現。
Operator
Operator
Andrea Alfonso, UBS.
Andrea Alfonso,瑞銀(UBS)。
Andrea Alfonso - Analyst
Andrea Alfonso - Analyst
Hi, good morning, guys. I just have a quick question around margins. So the gross margins, you did $71.8 this quarter, and it looks like you're updated guidance calls for $71.5 for the full year. I know you don't provide quarterly guidance, but just sort of looking at the trajectory for the remainder of the year, it does look like you're lapping a pretty tough comp in 2Q. I guess more broadly, how do you think about that trajectory and.
嗨,早安,各位。我有一個關於毛利率的簡短問題。所以本季毛利率你們做到 71.8%,而你們更新後的全年指引看起來是 71.5%。我知道你們不提供季度指引,但就今年剩餘期間的走勢來看,似乎第二季(2Q)會遇到一個相當艱難的比較基期。我想更廣泛地問,你們如何看待這個走勢,以及。
Sort of frame the levers that you have at your disposal to deliver there, given that pressure on some of your higher gross margin products? And then if I could squeeze in a separate housekeeping question, if you could just confirm that the 2% to 5% revenue growth outlook constant currency does not include any benefit from Neogen potentially closing in the second-half. Thank you so much, guys.
在一些高毛利產品承壓的情況下,請協助框架說明你們可用來達成目標的槓桿有哪些?另外如果我可以再塞一個行政性問題:可否請你們確認,以固定匯率計算的 2% 到 5% 營收成長展望,並未包含 Neogen 可能在下半年完成交割所帶來的任何效益?非常感謝,各位。
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Wetteny Joseph - Chief Financial Officer, Executive Vice President
Sure, I'll take both of those. If you look at our gross margins in the quarter, they were down about 10 basis points. But if you strip out the impact of FX, they're actually up about 140 basis points. So we have been very pleased with the execution across our manufacturing.
好的,這兩題我都來回答。如果你看我們本季的毛利率,大約下降了 10 個基點。但如果剔除匯率(FX)的影響,實際上是上升了約 140 個基點。因此,我們對於製造端的執行表現一直非常滿意。
Enterprise, and certainly you see that reflected in our performance in the quarter. We will continue to drive actions across the company, including in this segment, that will contribute to the performance for the year and the leverage that we have on the P&L. Do keep in mind that the mix in terms of products is an element to consider here. As you've seen in our guidance, and as I shared just a moment ago, we expect livestock continue to drive momentum. Here and grow faster than companion animal.
在整個企業範圍內,當然你也能在本季的表現中看到反映。我們將持續在全公司推動各項行動,包括在這個部門,這些都將有助於全年表現以及我們在損益表(P&L)上的營運槓桿。也請記得,產品組合的結構(mix)是此處需要考量的一個因素。如同你在我們的指引中所看到的,以及我剛才提到的,我們預期經濟動物(livestock)將持續帶動動能。並且成長速度快於伴侶動物(companion animal)。
There is some mixed impact to that with respect to what you see in gross margins. And in terms of FX, you've seen the US dollar impact in terms of revenue, but that has some converse effects when you get down to cost of sales. So that is a consideration here as well in terms of what you're comparing in terms of comps as we go through the rest of the year. But very pleased with the performance in terms of what we're doing on cost of sales, despite the mix that we see. And some geographical implications as well.
就您在毛利率上所看到的而言,這其中有一些混合性的影響。就外匯而言,您已看到美元對營收的影響,但當往下到銷貨成本時,會出現一些相反方向的效果。因此,當我們走過今年剩餘時間、比較各期可比基數時,這也是需要納入考量的一點。但就我們在銷貨成本方面所做的工作而言,儘管我們看到產品組合的影響,我們對表現仍非常滿意。此外也有一些地理區域方面的影響。
With respect to the guidance range on two to five, we do take a number of factors into consideration, including when competitive launches are going to come in, how aggressive they'll be. And so that range, which we widen by a point here for the uncertainty associated with those, is inherent. So within the guidance range, you could have the impact of potential, the closing of the deal with Neogen within that range.
關於2%到5%的指引區間,我們確實會將多項因素納入考量,包括競品何時推出、其進取程度會有多高。因此,這個區間我們在此因相關不確定性而擴大了1個百分點,這種不確定性是內含其中的。所以在該指引區間內,您也可能會看到潛在影響,例如與Neogen交易完成所帶來的影響也會落在這個區間之內。
Operator
Operator
Steve Scala, TD Cowen.
Steve Scala,TD Cowen。
Unidentified Participant
Unidentified Participant
Hi, this is Chris on for Steve Scala. Thank you for taking our questions. First, what is the level of interest and confidence in FTC approval of large-scale transformational business development? And second, do you see any opportunity to significantly pull forward merge timelines for products for new markets like renal and oncology, e.g., by changing trial designs or filing based on surrogate endpoints?
您好,我是代替Steve Scala提問的Chris。感謝您回答我們的問題。第一,對於大型、具轉型性的業務發展案,您對FTC核准的興趣與信心程度如何?第二,對於腎臟與腫瘤等新市場的產品,您是否看到有機會大幅提前合併時程/推進時程,例如透過改變試驗設計或以替代終點為基礎提出申請?
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
So, Sharon, let me start with your BD question. As always, our focus is on incremental BD. We don't see transformational BD as a major strategy for the company. As we've spoken about before from a capital allocation perspective, first and foremost, we are investing in our business. We obviously will continue to look at business development. And I think Neogen is a great example where we think there's incremental technologies.
Sharon,讓我先從您關於BD的問題開始。一如既往,我們的重點在於增量式的BD。我們不將轉型式BD視為公司的主要策略。如同我們先前從資本配置的角度所談到的,首要之務是投資於我們的業務。我們當然也會持續尋找業務發展機會。我認為Neogen就是一個很好的例子,我們認為其中有增量技術。
Or additional portfolios, such as what we've done in Australia for sheep, et cetera. So we'll continue to look for that. You should not expect large transformational BD. I think the deal like Neogen is what our sweet spot has historically been and will continue to be.
或是額外的產品組合,例如我們在澳洲針對綿羊所做的等等。因此我們會持續尋找這類機會。您不應期待大型的轉型式BD。我認為像Neogen這樣的交易,歷來一直是我們的甜蜜點,未來也會持續如此。
Is there a second part of your question? I think we're good.
您的問題還有第二部分嗎?我想我們這邊可以了。
Unidentified Participant
Unidentified Participant
Just some launch timelines and potential to pull forward filings for some of the newer market products, the pull forward.
只是關於一些上市時程,以及是否有可能提前為一些較新市場產品提出申請的時點,也就是提前推進。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
Sure. We're always focused as we think about our pipeline of, how we can pull forward. I would say anything that you see in the next few years is already in clinical trials. We're certainly partnering with the FDA, myself, and the other industry leaders to look at ways to speed innovation and to find new innovation pathways with the FDA. We're certainly leveraging AI, as I've spoken about. For within our portfolio, both in discovery, research, development, and importantly, preparing our dossiers for submission. We think all that can certainly speed it up, and we're also focused on, once we get approval, how we can speed time from approval to end market across our portfolio.
當然。在思考我們的研發管線時,我們一直專注於如何能夠提前推進。我會說,您在未來幾年內看到的任何項目,目前都已在進行臨床試驗。我們也確實正與FDA合作——包括我本人以及其他產業領袖——共同尋找加速創新的方法,並與FDA探索新的創新途徑。我們也確實如我先前所提到的,正在運用AI。在我們的產品組合中,涵蓋探索、研究、開發,以及重要的:準備提交所需的申報資料。我們認為這些都能確實加快速度;同時我們也聚焦於,一旦取得核准,如何在整個產品組合中加速從核准到終端市場的時間。
Operator
Operator
Thank you. At this time, we've reached our allotted time for questions. I'll now turn the call back over to Kristin for any additional or closing remarks.
謝謝。此時,我們已到達提問的預定時間。我現在把電話交回給Kristin,請她做任何補充或結語。
Kristin Peck - Chief Executive Officer, Director
Kristin Peck - Chief Executive Officer, Director
As always, everyone, thank you for your questions and your continued interest in Zoetis. I do want to recognize before we close our colleagues around the world whose commitment to their customers and their resilience, has really helped us navigate this environment. We will continue to keep you updated on our progress and our priorities. We are focused on executing with discipline to position the business to return to growth, and we remain committed to delivering long-term value for our shareholders. Thanks so much for joining us today.
一如既往,各位,感謝你們的提問以及對Zoetis持續的關注。在我們結束之前,我確實想表揚全球各地的同仁;他們對客戶的投入與韌性,確實幫助我們在此環境中順利前行。我們將持續向各位更新我們的進展與優先事項。我們專注於以紀律執行,讓業務定位回到成長軌道,同時我們仍致力於為股東創造長期價值。非常感謝各位今天加入。
Operator
Operator
Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.
謝謝。今天的會議到此結束。感謝各位的時間與參與。您現在可以中斷連線。